BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 79 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q1 2021. The put-call ratio across all filers is 1.25 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $35,118 | -87.6% | 175,504 | +27.6% | 0.00% | – |
| Q2 2023 | $283,446 | +765970.3% | 137,595 | +1125.6% | 0.00% | – |
| Q1 2023 | $37 | -45.6% | 11,227 | -73.0% | 0.00% | – |
| Q4 2022 | $68 | -100.0% | 41,618 | -71.0% | 0.00% | – |
| Q3 2022 | $634,000 | +108.6% | 143,359 | +30.3% | 0.00% | – |
| Q2 2022 | $304,000 | -36.0% | 109,996 | -22.1% | 0.00% | – |
| Q1 2022 | $475,000 | -21.0% | 141,253 | -5.9% | 0.00% | – |
| Q4 2021 | $601,000 | +21.2% | 150,166 | -0.1% | 0.00% | – |
| Q3 2021 | $496,000 | -64.9% | 150,327 | -59.5% | 0.00% | -100.0% |
| Q2 2021 | $1,412,000 | +493.3% | 371,460 | +605.4% | 0.00% | – |
| Q4 2020 | $238,000 | +47.8% | 52,662 | +266.4% | 0.00% | – |
| Q2 2020 | $161,000 | -82.5% | 14,373 | -92.7% | 0.00% | -100.0% |
| Q1 2020 | $919,000 | – | 198,052 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SABBY MANAGEMENT, LLC | 242,850 | $923,000 | 0.13% |
| ABNER HERRMAN & BROCK LLC | 241,500 | $918,000 | 0.13% |
| Weaver Consulting Group | 48,881 | $186,000 | 0.10% |
| Tibra Equities Europe Ltd | 87,000 | $331,000 | 0.10% |
| Ikarian Capital, LLC | 293,200 | $1,115,000 | 0.09% |
| GSA CAPITAL PARTNERS LLP | 60,238 | $229,000 | 0.03% |
| Ergoteles LLC | 124,329 | $472,000 | 0.01% |
| CFO4Life Group, LLC | 12,003 | $46,000 | 0.01% |
| HighPoint Advisor Group LLC | 17,033 | $65,000 | 0.01% |
| BOOTHBAY FUND MANAGEMENT, LLC | 32,836 | $125,000 | 0.00% |